Displaying drugs 7551 - 7575 of 12991 in total
alpha-Hydroxy glycineamide
Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid formation. It also has an effect on viral gp160 envelope protein.
Investigational
Matched Description: … metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 …
N-(carboxycarbonyl)-D-phenylalanine
N-(carboxycarbonyl)-D-phenylalanine is a solid. This compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. It targets the protein hypoxia-inducible factor 1-alpha inhibitor.
Experimental
Matched Description: … It targets the protein hypoxia-inducible factor 1-alpha inhibitor. …
Cetrelimab
Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).
Investigational
Matched Description: … Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 …
Gemogenovatucel-T
Gemogenovatucel-T is a bi-shRNA furin/Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented autologous tumour cell vaccine. Furin is a convertase involved in the activation of TGFβ-1 and TGFβ-2. Gemogenovatucel-T is being investigated in the treatment of various cancers.
Investigational
Matched Description: … Furin is a convertase involved in the activation of TGFβ-1 and TGFβ-2. …
Zinpentraxin alfa
Zinpentraxin alfa is a recombinant form of PTX-2, a naturally circulating human protein. It is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis).
Investigational
N(4)-Adenosyl-N(4)-methyl-2,4-diaminobutanoic acid
N(4)-adenosyl-n(4)-methyl-2,4-diaminobutanoic acid is a solid. This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar.
Experimental
Matched Name: … N(4)-Adenosyl-N(4)-methyl-2,4-diaminobutanoic acid …
Matched Iupac: … (2S)-2-amino-4-({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl}(methyl)amino …
Matched Description: … N(4)-adenosyl-n(4)-methyl-2,4-diaminobutanoic acid is a solid. …
Matched Iupac: … (2S)-2-amino-4-({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl}(methyl)amino …
Matched Description: … N(4)-adenosyl-n(4)-methyl-2,4-diaminobutanoic acid is a solid. …
N-Formylmethionine
N-Formylmethionine is effective in the initiation of protein synthesis. The initiating methionine residue enters the ribosome as N-formylmethionyl tRNA. This process occurs in Escherichia coli and other bacteria as well as in the mitochondria of eucaryotic cells.
Experimental
Matched Synonyms: … (2S)-2-(formylamino)-4-(methylthio)butanoic acid …
Matched Iupac: … (2S)-2-formamido-4-(methylsulfanyl)butanoic acid …
Matched Iupac: … (2S)-2-formamido-4-(methylsulfanyl)butanoic acid …
Diloxanide
Diloxanide (as Diloxanide furoate) is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections. Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977...
Experimental
Matched Iupac: … 2,2-dichloro-N-(4-hydroxyphenyl)-N-methylacetamide …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
ABX1100
ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle. It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.
Investigational
Matched Description: … investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 …
Tezacitabine
A synthetic purine nucleoside analogue with potential antineoplastic activity.
Investigational
Matched Iupac: … 4-amino-1-[(2R,3E,4S,5R)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Sorivudine
Sorivudine has been used in trials studying the treatment of Chickenpox and HIV Infections.
Investigational
Matched Iupac: … 5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
MONOGALACTOSYL-DIACYLGLYCEROL
Experimental
Matched Iupac: … (2S)-1-(tridecanoyloxy)-3-{[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2 …
Laninamivir
Laninamivir has been used in trials studying the treatment of Influenza.
Investigational
Matched Iupac: … (2R,3R,4S)-4-carbamimidamido-2-[(1R,2R)-2,3-dihydroxy-1-methoxypropyl]-3-acetamido-3,4-dihydro-2H-pyran …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Tegoprazan
Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.[A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.[A234215,...
Investigational
Matched Iupac: … 7-{[(4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-yl]oxy}-N,N,2-trimethyl-1H-1,3-benzodiazole-5-carboxamide …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
ATL1101
ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.
Investigational
Matched Description: … ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, …
Linsitinib
An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.
Investigational
Matched Iupac: … (1s,3r)-3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol …
Matched Description: … An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
PF-06273340
Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)).
Investigational
Matched Iupac: … N-{5-[2-amino-7-(1-hydroxy-2-methylpropan-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]pyridin-3-yl}- …
Matched Description: … of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
SC-74020
Experimental
Matched Iupac: … N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl][2-(morpholin-4-yl)ethyl]sulfamoyl}phenyl)-4-pentylbenzamide …
SNX-5422
SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Investigational
Matched Iupac: … (1r,4r)-4-({2-carbamoyl-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl] …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
SRT-2104
SRT2104 has been investigated for the basic science and treatment of Sepsis, PSORIASIS, Atrophy, Muscular, and Diabetes Mellitus, Type 2.
Investigational
Matched Iupac: … 4-methyl-N-(2-{3-[(morpholin-4-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)-2-(pyridin-3-yl)-1,3 …
STRO-001
Investigational
SRP-9005
SRP-9005 is a rAAVrh74 vector containing a codon-optimized human SGCG transgene. Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.
Investigational
SPK-7001
Investigational
SUVN-502
SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer’s and Schizophrenia, an unmet medical need.
Investigational
Matched Iupac: … 1-(2-bromobenzenesulfonyl)-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]-1H-indole …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Displaying drugs 7551 - 7575 of 12991 in total